In soft tissue sarcomas of the trunk or extremities, a neoadjuvant chemotherapy combination of epirubicin plus ifosfamide improves outcomes relative to treatments based on histology, according to data from a multicenter trial. The result was the opposite of the study’s hypothesis, but the advantage was so great in favor of the anthracycline and ifosfamide combination that the trial was terminated early.
With conflicting results from previous studies, there has been little consistency in